167 related articles for article (PubMed ID: 16690463)
1. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia.
Jelesoff NE; Ballantyne CM; Xydakis AM; Chiou P; Jones PH; Guyton JR
Endocr Pract; 2006; 12(2):159-64. PubMed ID: 16690463
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
[TBL] [Abstract][Full Text] [Related]
3. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
AIM-HIGH Investigators
Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
[TBL] [Abstract][Full Text] [Related]
4. Extended-release niacin or ezetimibe and carotid intima-media thickness.
Taylor AJ; Villines TC; Stanek EJ; Devine PJ; Griffen L; Miller M; Weissman NJ; Turco M
N Engl J Med; 2009 Nov; 361(22):2113-22. PubMed ID: 19915217
[TBL] [Abstract][Full Text] [Related]
5. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
6. Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance.
Rivers SM; Kane MP; Busch RS; Bakst G; Hamilton RA
Endocr Pract; 2007; 13(1):11-6. PubMed ID: 17360295
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
Grundy SM; Vega GL; McGovern ME; Tulloch BR; Kendall DM; Fitz-Patrick D; Ganda OP; Rosenson RS; Buse JB; Robertson DD; Sheehan JP;
Arch Intern Med; 2002 Jul; 162(14):1568-76. PubMed ID: 12123399
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy for combined dyslipidemia.
Xydakis AM; Ballantyne CM
Am J Cardiol; 2002 Nov; 90(10B):21K-29K. PubMed ID: 12467937
[TBL] [Abstract][Full Text] [Related]
10. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
11. Practical management of dyslipidemia with elevated lipoprotein(a).
Riche DM; East HE; Priest HM
J Am Pharm Assoc (2003); 2008; 48(6):803-7. PubMed ID: 19019811
[TBL] [Abstract][Full Text] [Related]
12. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
Morgan JM; Capuzzi DM; Guyton JR
Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
[TBL] [Abstract][Full Text] [Related]
13. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
Le NA; Jin R; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
J Am Heart Assoc; 2013 Aug; 2(4):e000037. PubMed ID: 23926117
[TBL] [Abstract][Full Text] [Related]
14. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ
J Am Coll Cardiol; 2010 Jun; 55(24):2721-6. PubMed ID: 20399059
[TBL] [Abstract][Full Text] [Related]
15. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
Capuzzi DM; Morgan JM; Weiss RJ; Chitra RR; Hutchinson HG; Cressman MD
Am J Cardiol; 2003 Jun; 91(11):1304-10. PubMed ID: 12767421
[TBL] [Abstract][Full Text] [Related]
17. Use of combination therapy for dyslipidemia: a lipid clinic approach.
Brown AS
Am J Cardiol; 2002 Nov; 90(10B):44K-49K. PubMed ID: 12467939
[TBL] [Abstract][Full Text] [Related]
18. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia.
Gagné C; Bays HE; Weiss SR; Mata P; Quinto K; Melino M; Cho M; Musliner TA; Gumbiner B;
Am J Cardiol; 2002 Nov; 90(10):1084-91. PubMed ID: 12423708
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study).
Zieve F; Wenger NK; Ben-Yehuda O; Constance C; Bird S; Lee R; Hanson ME; Jones-Burton C; Tershakovec AM
Am J Cardiol; 2010 Mar; 105(5):656-63. PubMed ID: 20185012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]